UCB Trading (Shanghai) Co., Ltd.

Headquartered in Brussels, Belgium, UCB is a global biopharmaceutical company focused on developing innovative drugs and therapies for severe diseases of the immune system and central nervous system. Currently, UCB employs approximately 7,600 people worldwide, operates in nearly 40 countries, and invests around 25% of its annual sales in research and development, continuously innovating. UCB's global sales in 2019 exceeded €4.9 billion, and it is listed on the European stock exchange (UCB).

UCB entered the Chinese market and began operations in the early 1990s. In 1996, UCB established its first office in Shanghai. With the acquisition of the German company Schwarz Pharma and its production facility in Zhuhai in 2006, and the launch of a blockbuster anti-epileptic drug the following year, UCB quickly became a rapidly growing pharmaceutical company in China.

Today, UCB China is headquartered in Shanghai, with regional offices in Beijing, Chengdu, and Guangzhou, and a new factory in Zhuhai. Through the joint efforts of its employees and close cooperation with partners, UCB China has made positive contributions to improving the lives of millions of patients. Looking ahead, UCB will continue to introduce more innovative drugs and solutions in neurology, immunology, and bone health to the Chinese market, benefiting even more patients.